Global Application Container Market to Reach $9.7 Billion by 2027

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 9. - Influencer Pool: 6613. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, March 30, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Anti-Inflammatory Therapeutics Industry" - https://www.reportlinker.com/p06039956/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

• Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

• Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

• Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

• Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

• Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.

Abstract:
- Global Anti-Inflammatory Therapeutics Market to Reach $135.5 Billion by 2027
- Amid the COVID-19 crisis, the global market for Anti-Inflammatory Therapeutics estimated at US$97.8 Billion in the year 2020, is projected to reach a revised size of US$135.5 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027. Anti-Inflammatory Biologics, one of the segments analyzed in the report, is projected to record a 5.2% CAGR and reach US$67.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment is readjusted to a revised 4.5% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $26.5 Billion, While China is Forecast to Grow at 7.3% CAGR
- The Anti-Inflammatory Therapeutics market in the U.S. is estimated at US$26.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$27.7 Billion by the year 2027 trailing a CAGR of 7.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 4.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.
- Corticosteroids Segment to Record 4.2% CAGR
- In the global Corticosteroids segment, USA, Canada, Japan, China and Europe will drive the 3.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$12.4 Billion in the year 2020 will reach a projected size of US$16.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$18 Billion by the year 2027, while Latin America will expand at a 5.2% CAGR through the analysis period.

- Select Competitors (Total 42 Featured) -

• AbbVie, Inc.

• Amgen, Inc.

• AstraZeneca PLC

• Eli Lilly and Company

• F. Hoffmann-La Roche AG

• GlaxoSmithKline PLC

• Johnson & Johnson

• Merck & Co., Inc.

• Novartis AG

• Pfizer, Inc.

Read the full report: https://www.reportlinker.com/p06039956/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Anti-Inflammatory
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Anti-Inflammatory
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Anti-Inflammatory
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Anti-Inflammatory
Biologics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Anti-Inflammatory Biologics
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Anti-Inflammatory
Biologics by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 7: World Current & Future Analysis for Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) by Geographic Region -
Percentage Breakdown of Value Sales for USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Corticosteroids
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Corticosteroids by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Corticosteroids by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Arthritis by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Arthritis by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Arthritis by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Respiratory
Diseases by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Respiratory Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Respiratory Diseases by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Multiple
Sclerosis by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Multiple Sclerosis by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Multiple Sclerosis by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Psoriasis by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Psoriasis by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Psoriasis by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Inflammatory
Bowel Disease by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Inflammatory Bowel Disease
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Inflammatory Bowel
Disease by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 28: World Current & Future Analysis for Other Indications
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 29: World Historic Review for Other Indications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Other Indications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 31: USA Current & Future Analysis for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Anti-Inflammatory
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Anti-Inflammatory Biologics, Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the
Years 2012, 2020 & 2027

Table 34: USA Current & Future Analysis for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Anti-Inflammatory
Therapeutics by Indication - Percentage Breakdown of Value
Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis,
Psoriasis, Inflammatory Bowel Disease and Other Indications for
the Years 2012, 2020 & 2027

CANADA
Table 37: Canada Current & Future Analysis for
Anti-Inflammatory Therapeutics by Drug Class -
Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) and Corticosteroids - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 38: Canada Historic Review for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 39: Canada 15-Year Perspective for Anti-Inflammatory
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Anti-Inflammatory Biologics, Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the
Years 2012, 2020 & 2027

Table 40: Canada Current & Future Analysis for
Anti-Inflammatory Therapeutics by Indication - Arthritis,
Respiratory Diseases, Multiple Sclerosis, Psoriasis,
Inflammatory Bowel Disease and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 41: Canada Historic Review for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Anti-Inflammatory
Therapeutics by Indication - Percentage Breakdown of Value
Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis,
Psoriasis, Inflammatory Bowel Disease and Other Indications for
the Years 2012, 2020 & 2027

JAPAN
Table 43: Japan Current & Future Analysis for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 44: Japan Historic Review for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 45: Japan 15-Year Perspective for Anti-Inflammatory
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Anti-Inflammatory Biologics, Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the
Years 2012, 2020 & 2027

Table 46: Japan Current & Future Analysis for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 48: Japan 15-Year Perspective for Anti-Inflammatory
Therapeutics by Indication - Percentage Breakdown of Value
Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis,
Psoriasis, Inflammatory Bowel Disease and Other Indications for
the Years 2012, 2020 & 2027

CHINA
Table 49: China Current & Future Analysis for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 50: China Historic Review for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 51: China 15-Year Perspective for Anti-Inflammatory
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Anti-Inflammatory Biologics, Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the
Years 2012, 2020 & 2027

Table 52: China Current & Future Analysis for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 53: China Historic Review for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 54: China 15-Year Perspective for Anti-Inflammatory
Therapeutics by Indication - Percentage Breakdown of Value
Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis,
Psoriasis, Inflammatory Bowel Disease and Other Indications for
the Years 2012, 2020 & 2027

EUROPE
Table 55: Europe Current & Future Analysis for
Anti-Inflammatory Therapeutics by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 56: Europe Historic Review for Anti-Inflammatory
Therapeutics by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 57: Europe 15-Year Perspective for Anti-Inflammatory
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia and
Rest of Europe Markets for Years 2012, 2020 & 2027

Table 58: Europe Current & Future Analysis for
Anti-Inflammatory Therapeutics by Drug Class -
Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) and Corticosteroids - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 59: Europe Historic Review for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 60: Europe 15-Year Perspective for Anti-Inflammatory
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Anti-Inflammatory Biologics, Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the
Years 2012, 2020 & 2027

Table 61: Europe Current & Future Analysis for
Anti-Inflammatory Therapeutics by Indication - Arthritis,
Respiratory Diseases, Multiple Sclerosis, Psoriasis,
Inflammatory Bowel Disease and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 62: Europe Historic Review for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 63: Europe 15-Year Perspective for Anti-Inflammatory
Therapeutics by Indication - Percentage Breakdown of Value
Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis,
Psoriasis, Inflammatory Bowel Disease and Other Indications for
the Years 2012, 2020 & 2027

FRANCE
Table 64: France Current & Future Analysis for
Anti-Inflammatory Therapeutics by Drug Class -
Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) and Corticosteroids - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 65: France Historic Review for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 66: France 15-Year Perspective for Anti-Inflammatory
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Anti-Inflammatory Biologics, Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the
Years 2012, 2020 & 2027

Table 67: France Current & Future Analysis for
Anti-Inflammatory Therapeutics by Indication - Arthritis,
Respiratory Diseases, Multiple Sclerosis, Psoriasis,
Inflammatory Bowel Disease and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 68: France Historic Review for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 69: France 15-Year Perspective for Anti-Inflammatory
Therapeutics by Indication - Percentage Breakdown of Value
Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis,
Psoriasis, Inflammatory Bowel Disease and Other Indications for
the Years 2012, 2020 & 2027

GERMANY
Table 70: Germany Current & Future Analysis for
Anti-Inflammatory Therapeutics by Drug Class -
Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) and Corticosteroids - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 71: Germany Historic Review for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 72: Germany 15-Year Perspective for Anti-Inflammatory
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Anti-Inflammatory Biologics, Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the
Years 2012, 2020 & 2027

Table 73: Germany Current & Future Analysis for
Anti-Inflammatory Therapeutics by Indication - Arthritis,
Respiratory Diseases, Multiple Sclerosis, Psoriasis,
Inflammatory Bowel Disease and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 74: Germany Historic Review for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 75: Germany 15-Year Perspective for Anti-Inflammatory
Therapeutics by Indication - Percentage Breakdown of Value
Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis,
Psoriasis, Inflammatory Bowel Disease and Other Indications for
the Years 2012, 2020 & 2027

ITALY
Table 76: Italy Current & Future Analysis for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 77: Italy Historic Review for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 78: Italy 15-Year Perspective for Anti-Inflammatory
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Anti-Inflammatory Biologics, Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the
Years 2012, 2020 & 2027

Table 79: Italy Current & Future Analysis for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 80: Italy Historic Review for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 81: Italy 15-Year Perspective for Anti-Inflammatory
Therapeutics by Indication - Percentage Breakdown of Value
Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis,
Psoriasis, Inflammatory Bowel Disease and Other Indications for
the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 82: UK Current & Future Analysis for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 83: UK Historic Review for Anti-Inflammatory Therapeutics
by Drug Class - Anti-Inflammatory Biologics, Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 84: UK 15-Year Perspective for Anti-Inflammatory
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Anti-Inflammatory Biologics, Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the
Years 2012, 2020 & 2027

Table 85: UK Current & Future Analysis for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 86: UK Historic Review for Anti-Inflammatory Therapeutics
by Indication - Arthritis, Respiratory Diseases, Multiple
Sclerosis, Psoriasis, Inflammatory Bowel Disease and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 87: UK 15-Year Perspective for Anti-Inflammatory
Therapeutics by Indication - Percentage Breakdown of Value
Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis,
Psoriasis, Inflammatory Bowel Disease and Other Indications for
the Years 2012, 2020 & 2027

SPAIN
Table 88: Spain Current & Future Analysis for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 89: Spain Historic Review for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 90: Spain 15-Year Perspective for Anti-Inflammatory
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Anti-Inflammatory Biologics, Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the
Years 2012, 2020 & 2027

Table 91: Spain Current & Future Analysis for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 92: Spain Historic Review for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 93: Spain 15-Year Perspective for Anti-Inflammatory
Therapeutics by Indication - Percentage Breakdown of Value
Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis,
Psoriasis, Inflammatory Bowel Disease and Other Indications for
the Years 2012, 2020 & 2027

RUSSIA
Table 94: Russia Current & Future Analysis for
Anti-Inflammatory Therapeutics by Drug Class -
Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) and Corticosteroids - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 95: Russia Historic Review for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 96: Russia 15-Year Perspective for Anti-Inflammatory
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Anti-Inflammatory Biologics, Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids for the
Years 2012, 2020 & 2027

Table 97: Russia Current & Future Analysis for
Anti-Inflammatory Therapeutics by Indication - Arthritis,
Respiratory Diseases, Multiple Sclerosis, Psoriasis,
Inflammatory Bowel Disease and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 98: Russia Historic Review for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 99: Russia 15-Year Perspective for Anti-Inflammatory
Therapeutics by Indication - Percentage Breakdown of Value
Sales for Arthritis, Respiratory Diseases, Multiple Sclerosis,
Psoriasis, Inflammatory Bowel Disease and Other Indications for
the Years 2012, 2020 & 2027

REST OF EUROPE
Table 100: Rest of Europe Current & Future Analysis for
Anti-Inflammatory Therapeutics by Drug Class -
Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) and Corticosteroids - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 101: Rest of Europe Historic Review for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 102: Rest of Europe 15-Year Perspective for
Anti-Inflammatory Therapeutics by Drug Class - Percentage
Breakdown of Value Sales for Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids for the Years 2012, 2020 & 2027

Table 103: Rest of Europe Current & Future Analysis for
Anti-Inflammatory Therapeutics by Indication - Arthritis,
Respiratory Diseases, Multiple Sclerosis, Psoriasis,
Inflammatory Bowel Disease and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 104: Rest of Europe Historic Review for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 105: Rest of Europe 15-Year Perspective for
Anti-Inflammatory Therapeutics by Indication - Percentage
Breakdown of Value Sales for Arthritis, Respiratory Diseases,
Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease and
Other Indications for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 106: Asia-Pacific Current & Future Analysis for
Anti-Inflammatory Therapeutics by Geographic Region -
Australia, India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 107: Asia-Pacific Historic Review for Anti-Inflammatory
Therapeutics by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 108: Asia-Pacific 15-Year Perspective for
Anti-Inflammatory Therapeutics by Geographic Region -
Percentage Breakdown of Value Sales for Australia, India, South
Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 &
2027

Table 109: Asia-Pacific Current & Future Analysis for
Anti-Inflammatory Therapeutics by Drug Class -
Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) and Corticosteroids - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 110: Asia-Pacific Historic Review for Anti-Inflammatory
Therapeutics by Drug Class - Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 111: Asia-Pacific 15-Year Perspective for
Anti-Inflammatory Therapeutics by Drug Class - Percentage
Breakdown of Value Sales for Anti-Inflammatory Biologics,
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
Corticosteroids for the Years 2012, 2020 & 2027

Table 112: Asia-Pacific Current & Future Analysis for
Anti-Inflammatory Therapeutics by Indication - Arthritis,
Respiratory Diseases, Multiple Sclerosis, Psoriasis,
Inflammatory Bowel Disease and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 113: Asia-Pacific Historic Review for Anti-Inflammatory
Therapeutics by Indication - Arthritis, Respiratory Diseases,

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06039956/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001